• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by ICON plc

    5/15/26 4:11:48 PM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $ICLR alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    ICON plc

    (Name of Issuer)


    Ordinary shares, par value 0.06 euros

    (Title of Class of Securities)




    G4705A100

    (CUSIP Number)
    03/31/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    G4705A100


    1Names of Reporting Persons

    HARRIS ASSOCIATES L P
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    4,349,124.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    4,351,317.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,351,317.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.7 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    CUSIP Number(s):
    G4705A100


    1Names of Reporting Persons

    Harris Associates, Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    4,349,124.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    4,351,317.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,351,317.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.7 %
    12Type of Reporting Person (See Instructions)

    CO


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    ICON plc
    (b)Address of issuer's principal executive offices:

    South County Business Park, Leopardstown, Dublin 18, L2, D18 X5R3.
    Item 2. 
    (a)Name of person filing:

    Harris Associates L.P. ("Harris") Harris Associates, Inc. ("General Partner") **Harris Associates, Inc., for itself and as General Partner
    (b)Address or principal business office or, if none, residence:

    111 South Wacker Drive Suite 4600, Chicago, IL 60606
    (c)Citizenship:

    See Item 4 on the cover page(s) hereto.
    (d)Title of class of securities:

    Ordinary shares, par value 0.06 euros
    (e)CUSIP Number(s):

    G4705A100
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    By reason of advisory and other relationships with the person who owns the Shares, Harris may be deemed to be the beneficial owner of the shares specified in Item 9 on the cover page(s) hereto. Harris has been granted the power to vote Shares in circumstances it determines to be appropriate in connection with assisting its advised clients to whom it renders financial advice in the ordinary course of business, by either providing information or advice to the persons having such power, or by exercising the power to vote.
    (b)Percent of class:

    See Item 11 on the cover page(s) hereto.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See Item 5 on the cover page(s) hereto.

     (ii) Shared power to vote or to direct the vote:

    See Item 6 on the cover page(s) hereto.

     (iii) Sole power to dispose or to direct the disposition of:

    See Item 7 on the cover page(s) hereto.

     (iv) Shared power to dispose or to direct the disposition of:

    See Item 8 on the cover page(s) hereto.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    HARRIS ASSOCIATES L P
     
    Signature:Joseph J. Allessie
    Name/Title:Joseph J. Allessie, General Counsel and Secretary
    Date:05/15/2026
     
    Harris Associates, Inc.
     
    Signature:Joseph J. Allessie
    Name/Title:Joseph J. Allessie, General Counsel and Secretary
    Date:05/15/2026
    Get the next $ICLR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ICLR

    DatePrice TargetRatingAnalyst
    5/18/2026$123.00Sector Perform
    RBC Capital Mkts
    3/26/2026$130.00Market Perform → Outperform
    BMO Capital Markets
    2/23/2026$135.00Hold → Buy
    Jefferies
    2/18/2026$120.00Hold → Buy
    TD Cowen
    2/17/2026$100.00Buy → Neutral
    Rothschild & Co Redburn
    2/12/2026$105.00Outperform → Market Perform
    Leerink Partners
    2/12/2026$75.00Neutral → Underperform
    BofA Securities
    1/8/2026$222.00Buy → Hold
    Truist
    More analyst ratings

    $ICLR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ICON Schedules Fourth Quarter and Full Year 2025 Earnings Conference Call and Acknowledges Receipt of Deficiency Notice from Nasdaq

    ICON plc (NASDAQ:ICLR), a world-leading clinical research organization, today announced that it will release financial results for the fourth quarter and full year 2025 results after the market closes on Wednesday, May 27, 2026. The Company will hold a conference call and webcast to discuss its financial results and performance on Thursday, May 28, 2026 at 8:00am ET. The Company also announced that, as expected, as a consequence of not yet having filed its Annual Report on Form 20-F for the year ended December 31, 2025 (the "Form 20-F"), the Company has received a written notice from Nasdaq indicating that it is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Listing Rule"), w

    5/26/26 4:05:00 PM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    ICON expands US early phase research capabilities with new clinic and outpatient centres

    New, 69.5K square-foot, state-of-the-art clinic in Texas integrates clinical, laboratory, and pharmacy infrastructure all under one roof Two new satellite outpatient clinics in Texas and Kansas will further expand recruitment reach and reduce visit burden ICON plc (NASDAQ:ICLR), a world-leading clinical research organisation, today announced the expansion of its early phase capabilities with the opening of a new, state-of-the-art Clinical Research Unit (CRU) in San Antonio, Texas, as well as new satellite outpatient clinics in Houston, Texas and Lawrence, Kansas. These new, purpose-built clinics will significantly expand ICON's capacity to conduct first-in-human, healthy participant,

    5/13/26 8:00:00 AM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    HealthVerity to Acquire Symphony Health, Uniting Clinical Data and Commercial Analytics to Accelerate Breakthroughs Across the Healthcare Ecosystem

    Philadelphia, PA, May 05, 2026 (GLOBE NEWSWIRE) -- HealthVerity, Inc., the leader in privacy-protected real-world data exchange and patient identity solutions, today announced that it has entered into a definitive agreement to acquire Symphony Health Solutions Corporation, a commercial healthcare data business formerly part of ICON plc (NASDAQ:ICLR). The transaction is subject to customary closing conditions and is expected to close in May 2026. The transaction will define the next era of healthcare real-world data by bringing together HealthVerity's clinical data depth and experience with Symphony Health's commercial insights and scale into a single, connected view of the patient and

    5/5/26 8:00:00 AM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ICLR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RBC Capital Mkts resumed coverage on ICON plc with a new price target

    RBC Capital Mkts resumed coverage of ICON plc with a rating of Sector Perform and set a new price target of $123.00

    5/18/26 8:34:11 AM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    ICON plc upgraded by BMO Capital Markets with a new price target

    BMO Capital Markets upgraded ICON plc from Market Perform to Outperform and set a new price target of $130.00

    3/26/26 8:38:54 AM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    ICON plc upgraded by Jefferies with a new price target

    Jefferies upgraded ICON plc from Hold to Buy and set a new price target of $135.00

    2/23/26 8:29:27 AM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ICLR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Murphy Ronan Martin

    4 - ICON PLC (0001060955) (Issuer)

    5/15/26 8:39:02 AM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 4 filed by Director Climax John Dr

    4 - ICON PLC (0001060955) (Issuer)

    5/15/26 8:38:31 AM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 4 filed by Director Mccague Eugene Pacelli

    4 - ICON PLC (0001060955) (Issuer)

    5/15/26 8:38:09 AM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ICLR
    SEC Filings

    View All

    SEC Form 6-K filed by ICON plc

    6-K - ICON PLC (0001060955) (Filer)

    5/27/26 4:41:05 PM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Amendment: SEC Form 6-K/A filed by ICON plc

    6-K/A - ICON PLC (0001060955) (Filer)

    5/27/26 4:29:30 PM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 20-F filed by ICON plc

    20-F - ICON PLC (0001060955) (Filer)

    5/27/26 4:24:40 PM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ICLR
    Leadership Updates

    Live Leadership Updates

    View All

    ICON Announces CEO Transition

    ICON plc (NASDAQ:ICLR), a world-leading clinical research organisation, today announced that Dr. Steve Cutler has informed the Board of his decision to retire as Chief Executive Officer and the Board has appointed Mr. Barry Balfe, ICON's Chief Operating Officer, to succeed Dr. Cutler as Chief Executive Officer effective 1 October 2025. Mr. Balfe has also been appointed to the Board. Dr. Cutler will continue to serve on the Board as a non-executive director to facilitate a smooth transition. Mr. Balfe has deep knowledge of the CRO industry and has served as ICON's Chief Operating Officer since January 2025. Prior to his appointment as Chief Operating Officer, Mr. Balfe was appointed to the

    9/4/25 8:00:00 AM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    ICON Announces Results of Annual General Meeting

    ICON plc (NASDAQ:ICLR), a world-leading clinical research organisation powered by healthcare intelligence, today announced that all resolutions at the Annual General Meeting of the company (AGM) held on July 22, 2025 were duly passed by shareholders. These resolutions were set out in the Notice of the AGM sent to shareholders dated June 11, 2025 and are available on the ICON plc website. Forms of Proxy were received by ICON plc before the meeting, appointing proxies and giving them the following voting instructions: RESOLUTION NUMBER RESOLUTION     TOTAL NUMBER OF VOTES     VOTE FOR     VOTE AGAINST     VOTE WITHHELD                   1.1

    7/23/25 4:20:00 PM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Anne Whitaker Appointed as Non-Executive Director

    MELBOURNE, Australia and INDIANAPOLIS, April 04, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, Telix, the Company) today announces the appointment of Anne Whitaker as a Non-Executive Director (NED) based in the United States, effective 7 April 20251. Ms. Whitaker is a seasoned healthcare leader and advisor with over 30 years' global corporate experience spanning large pharmaceutical, biotech and speciality pharmaceutical companies, including clinical research and manufacturing organizations. She has held Board positions on a range of Nasdaq-listed clinical and commercial stage life sciences companies. Ms. Whitaker is currently serving as a NED at Icon PLC

    4/3/25 6:13:56 PM ET
    $ICLR
    $TLX
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $ICLR
    Financials

    Live finance-specific insights

    View All

    ICON Schedules Fourth Quarter and Full Year 2025 Earnings Conference Call and Acknowledges Receipt of Deficiency Notice from Nasdaq

    ICON plc (NASDAQ:ICLR), a world-leading clinical research organization, today announced that it will release financial results for the fourth quarter and full year 2025 results after the market closes on Wednesday, May 27, 2026. The Company will hold a conference call and webcast to discuss its financial results and performance on Thursday, May 28, 2026 at 8:00am ET. The Company also announced that, as expected, as a consequence of not yet having filed its Annual Report on Form 20-F for the year ended December 31, 2025 (the "Form 20-F"), the Company has received a written notice from Nasdaq indicating that it is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Listing Rule"), w

    5/26/26 4:05:00 PM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    ICON Reports Third Quarter 2025 Results

    Highlights Quarter three revenue was $2,042.8 million representing an increase of 1.3% on quarter two 2025. Net income for the quarter was $2.4 million or $0.03 per diluted share. Quarter three adjusted EBITDA was $396.7 million or 19.4% of revenue, representing an increase of 0.2% on quarter two 2025. Quarter three adjusted net income was $258.8 million or $3.31 per diluted ordinary share. Gross business wins in the quarter of $2,986 million, representing an increase of 0.7% on quarter two 2025. Net business wins in the quarter of $2,086 million, representing an increase of 1.4% on quarter two 2025; a net book to bill in the quarter of 1.02. Net debt was $2.9 bil

    10/22/25 4:25:00 PM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    ICON plc Schedules Third Quarter 2025 Earnings Conference Call

    ICON plc, (NASDAQ:ICLR) a world-leading clinical research organisation, today announced that it will release its financial results for the third quarter 2025 after the market closes on Wednesday, October 22, 2025. The company will hold a conference call and webcast to discuss its financial results and performance on Thursday, October 23, 2025 at 8:00am ET. Any changes to this event and links to the live webcast will be posted on the Investor section of our website under "Events". A webcast replay of the conference call will be available approximately one hour following the conclusion of the call. About ICON plc ICON plc is a world-leading clinical research organisation. From molecule

    9/24/25 9:00:00 AM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ICLR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by ICON plc

    SC 13G/A - ICON PLC (0001060955) (Subject)

    11/12/24 11:54:03 AM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13G/A filed by ICON plc (Amendment)

    SC 13G/A - ICON PLC (0001060955) (Subject)

    2/9/24 11:49:03 AM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13G/A filed by ICON plc (Amendment)

    SC 13G/A - ICON PLC (0001060955) (Subject)

    1/30/24 12:11:57 PM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care